The deal aims to integrate the Contour Next-Gen and Contour Next One BGM systems into Avricore’s HealthTab PCOT platform. Both companies have the objective of supporting patients and pharmacists in Canada to better manage diabetes. The companies believe they can link daily blood glucose testing results and pattern history to a patient’s HealthTab account.
Additionally, the partnership seeks to support the utilization of each technology by enabling pharmacists and patients to take advantage of data insights.
“Health data silos are leading to terrible outcomes for patients, but with this collaboration, we can ensure patients and their pharmacists have the right information for better care decisions,” said Hector Bremner, CEO of Avricore Health. “This is also the first time we are integrating a device that is with the patient and not located in the pharmacy, opening doors for exciting possibilities for HealthTab.”
The companies say combining Ascensia BGM daily insights with HealthTab and its associated instruments could drive diabetes care. Data like HbA1c and lipids profile collected during consultations offer a robust personal health data tool against diabetes.
Avricore and Ascensia expect to finish the technical work and patient interface launch by the third quarter of this year. They intend to conduct ongoing work to identify ways to communicate and encourage patient engagement, too.
“At Ascensia we strive to make diabetes management as simple as possible. We enable people with diabetes, and their caregivers, to use data to make informed decisions with their healthcare provider. It is important to provide systems that make monitoring easier and well-suited to modern-day living,” said Annika Pawaroo, Head of Region Americas, Ascensia Diabetes Care. “This partnership is a vital step in elevating patient care delivery to the next level.”
